No Data
No Data
Yiteng Jia and "Transformation", the first shot of "value leap" was fired in the cold winter of biomedical capital.
With this integration, the new company's dual advantages in R&D and commercialization will make it more in line with the current market valuation trend for Biopharma companies, thereby possessing the potential for value reconstruction.
IPO outlook | There are hidden concerns behind high growth. How can the four-handed Yiteng Pharmaceutical tell a good listing story?
After a lapse of two years, Yiteng Pharmaceutical hit the Hong Kong Stock Exchange once again. The Zhitong Finance App noticed that recently Yiteng Pharmaceutical Group Co., Ltd. (hereinafter referred to as “Yiteng Pharmaceutical”) submitted a listing application to the main board of the Hong Kong Stock Exchange, with Morgan Stanley as the sole sponsor. It is worth mentioning that the company submitted prospectus to the Hong Kong Stock Exchange three times on September 23, 2020, March 29, 2021, and December 15, 2021, respectively. The company also successfully passed the hearing on June 25, 2021, but finally failed due to the failure to launch a prospectus. According to the prospectus, Yiteng Pharmaceutical was founded in 2001 and is a fully integrated biopharmaceutical company. The goal is
